YHB Investment Advisors Inc. Has $1,250,000 Stake in ABIOMED, Inc. (ABMD)

YHB Investment Advisors Inc. held its position in ABIOMED, Inc. (NASDAQ:ABMD) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,592 shares of the medical equipment provider’s stock at the end of the first quarter. YHB Investment Advisors Inc.’s holdings in ABIOMED were worth $1,250,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Gilder Gagnon Howe & Co. LLC raised its position in ABIOMED by 320.1% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 8,272 shares of the medical equipment provider’s stock worth $1,064,000 after buying an additional 6,303 shares in the last quarter. Dimensional Fund Advisors LP raised its position in ABIOMED by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 132,006 shares of the medical equipment provider’s stock worth $14,875,000 after buying an additional 4,990 shares in the last quarter. Marshall Wace LLP raised its position in ABIOMED by 56.3% in the fourth quarter. Marshall Wace LLP now owns 55,113 shares of the medical equipment provider’s stock worth $6,210,000 after buying an additional 19,858 shares in the last quarter. BKS Advisors LLC purchased a new position in ABIOMED during the third quarter worth $2,482,000. Finally, OMERS ADMINISTRATION Corp raised its position in ABIOMED by 245.9% in the third quarter. OMERS ADMINISTRATION Corp now owns 12,800 shares of the medical equipment provider’s stock worth $1,646,000 after buying an additional 9,100 shares in the last quarter. 92.67% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Shares of ABIOMED, Inc. (NASDAQ:ABMD) traded up 0.89% on Friday, hitting $134.43. 236,498 shares of the stock were exchanged. ABIOMED, Inc. has a one year low of $95.14 and a one year high of $134.91. The firm has a market capitalization of $5.86 billion, a PE ratio of 114.90 and a beta of 0.51. The company has a 50-day moving average price of $128.54 and a 200-day moving average price of $117.90.

ABIOMED (NASDAQ:ABMD) last posted its earnings results on Thursday, May 4th. The medical equipment provider reported $0.33 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.33. The company had revenue of $124.68 million during the quarter, compared to analysts’ expectations of $122.82 million. ABIOMED had a net margin of 11.63% and a return on equity of 12.35%. ABIOMED’s quarterly revenue was up 32.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.24 EPS. Equities research analysts expect that ABIOMED, Inc. will post $1.84 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “YHB Investment Advisors Inc. Has $1,250,000 Stake in ABIOMED, Inc. (ABMD)” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://transcriptdaily.com/2017/05/20/yhb-investment-advisors-inc-has-1250000-stake-in-abiomed-inc-abmd.html.

ABMD has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of ABIOMED from a “sell” rating to a “hold” rating in a research report on Monday, January 30th. Piper Jaffray Companies raised shares of ABIOMED from a “neutral” rating to an “overweight” rating and set a $145.00 price objective for the company in a research report on Thursday, April 6th. TheStreet raised shares of ABIOMED from a “c+” rating to a “b-” rating in a research report on Tuesday, February 21st. Finally, Leerink Swann upped their price objective on shares of ABIOMED from $140.00 to $150.00 and gave the company an “outperform” rating in a research report on Thursday, March 30th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $151.00.

In other news, VP Michael G. Howley sold 600 shares of the firm’s stock in a transaction dated Monday, May 8th. The shares were sold at an average price of $132.84, for a total transaction of $79,704.00. Following the completion of the sale, the vice president now owns 48,305 shares in the company, valued at approximately $6,416,836.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Michael G. Howley sold 18,279 shares of the firm’s stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $133.56, for a total transaction of $2,441,343.24. Following the sale, the vice president now owns 62,105 shares of the company’s stock, valued at approximately $8,294,743.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 63,629 shares of company stock valued at $8,312,580. 10.00% of the stock is currently owned by corporate insiders.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

12 Month Chart for NASDAQ:ABMD

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply